Sus Clinicals will present two sessions on the Oncopig Cancer Model® on Monday, March 25, at SIR2024 in Salt Lake City.

“Utility of Oncopig Liver and Lung Cancer Models for Device-based Therapeutic Studies”
 
Presented by Dr. Kyle Schachtschneider, Vice President of R&D and Services for Sus Clinicals. This study demonstrates the ability to successfully develop Oncopig® liver and lung tumors and track formation using clinically relevant imaging modalities. Tumors develop rapidly (within 2 weeks) and are readily targetable under ultrasound, CT, or fluoroscopic guidance, making this an ideal model for device-based therapeutic studies.

“Preclinical Evaluation of yttrium-90 Radioembolization in the Oncopig Liver Cancer Model”
 
Presented jointly by Sus Clinicals and ABK Biomedical, this study demonstrated the utility of the Oncopig liver cancer model for preclinical yttrium-90 radioembolization testing, with a strong correlation between the radiopacity on conventional CT and radioactivity on SPECT/CT imaging. The Oncopig liver cancer model represents a valuable tool for technical, analytical, and outcomes-based investigations aimed at optimizing clinical care with yttrium-90 radioembolization.

Sus Clinicals representatives will be available for discussions with attendees who may be interested in learning more about Oncopig-based capabilities. Please contact us to learn more.